S troke is one of the leading causes of morbidity and mortality worldwide, of which >80% are ischemic caused by obstruction of the cerebral arteries.
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DIP2A on brain ischemia has not been previously investigated nor the molecular mechanisms underlying the effects of FSTL1 on neuron apoptosis. The present study aims to investigate the neuroprotective effect and potential molecular mechanisms of FSTL1 in a rat middle cerebral artery occlusion (MCAO) model.
Materials and Methods

Animal Model and Experimental Protocol
All experiments were approved by the Institutional Animal Care and Use Committee of Loma Linda University. Sprague-Dawley male rats weighting 260 to 300 g were subjected to MCAO as previously described, 9 with some modifications. Briefly, anesthesia was induced intraperitoneally with ketamine (80 mg/kg) and xylazine (10 mg/kg) followed by atropine at a dose of 0.1 mg/kg. The right common carotid artery, internal carotid artery, and external carotid artery were surgically exposed. The external carotid artery was coagulated, and 4-0 nylon suture with silicon was inserted into the internal carotid artery through the external carotid artery stump to occlude the MCA. After 2 hours of MCAO, the suture was carefully removed to induce reperfusion. Sham rats underwent the same procedures except that the MCA was not occluded. After closing the skin incision, rats were kept at ≈37°C on an electric heating blanket and were housed separately until completely recovered from anesthetic.
To test whether delivery of FSTL1 protein affects acute brain ischemic injury in rats, male Sprague-Dawley rats were injected intracerebroventricularly with either 1 of 2 dosages of recombinant FSTL1 protein (R&D Systems, 100 or 300 mg/kg) or vehicle (0.1 mol/L PBS) at 1 hour after reperfusion.
siRNA Injection
Three different formats of FSTL1-small interfering RNA (siRNA) (OriGene Technologies) or DIP2A-siRNA (Santa Cruz Biotechnology) were applied 48 hours before MCAO by intracerebroventricular injection (ICV) as previously described. 10 A scalp incision was made along the midline, and a burr hole (1 mm) was drilled into the skull above the right hemisphere (1.0 mm lateral of the bregma). The FSTL1-siRNA or DIP2A-siRNA mixture or scramble-siRNA (100 pmol/2 μL) was delivered into the ipsilateral ventricle with a Hamilton syringe and administered for 2 minutes. The needle was left in place for an additional 5 minutes after injection to prevent possible leakage and was then slowly withdrawn after 4 minutes. After the needle was removed, the burr hole was sealed with bone wax. The incision was closed with sutures, and the rat was allowed to recover.
Neurological Scores
Twenty-four or 72 hours after MCAO, the Garcia test was performed by a blinded investigator as previously described with modifications. 11 The score given to each rat at completion of the evaluation was the summation of 7 individual test scores (spontaneous activity, symmetry in the movement of 4 limbs, forepaw outstretching, climbing, body proprioception, response to vibrissae touch, and beam walking). The neurological scoring ranged from 2 (most severe deficit) to 21 (maximum).
2,3,5-Triphenyltetrazolium Chloride Staining
Infarction volume was determined by staining with 2,3,5-triphenyltetrazolium chloride (Sigma) at 24 and 72 hours after MCAO as previously described with some modification. 11 Briefly, general anesthesia was reintroduced with a mixture of ketamine and xylazine and decapitated; the brains were rapidly removed and sectioned coronally into 2-mm thick slices starting from the frontal pole. Slices were stained with 2,3,5-triphenyltetrazolium chloride for 15 minutes at 37°C. The infarct and total hemispheric areas of each section were traced and analyzed using ImageJ (ImageJ, National Institutes of Health). The possible interference of brain edema with infarct volume was corrected by standard methods (whole contralateral hemisphere volume−nonischemic ipsilateral hemisphere volume), and the infracted volume was expressed as a ratio of the corrected infarct to the whole contralateral hemisphere.
Immunofluorescence Staining
Rats were euthanized 24 hours after MCAO for double immunofluorescence staining as previously described, 11 using the neuronal marker of neuronal nuclei (NeuN; Millipore), FSTL1 (sc-12542, Santa Cruz Biotechnology), and DIP2A (sc-6755, Santa Cruz Biotechnology). Brain sections were incubated with a mixture of either NeuN and FSTL1 or NeuN and DIP2A primary antibodies over night at 4°C, followed by a mixture of secondary antibodies for 1 hour at room temperature. Microphotographs were analyzed with a fluorescent microscope (Olympus OX51, Japan).
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling Staining
Twenty-four hours after MCAO, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed with In Situ Apoptosis Detection Kit (Roche) according to the manufacturer's instruction. Four images were taken from the ischemic border of each section using a ×40 objective lens and then the number of TUNEL-positive neurons and the number of TUNEL-positive nonneurons were counted. The total number of neurons and non-neurons in the ischemic hemisphere at ×40 magnification were counted in 3 arbitrary fields. The number of TUNEL-positive neurons or nonneurons was expressed as a ratio to that in MCAO+vehicle group, respectively.
Western Blots
Brain samples were collected 24 hours after MCAO. Proteins of the ipsilateral hemisphere were extracted by homogenizing in radio-immunoprecipitation assay lysis buffer (sc-24948, Santa Cruz Biotechnology). Western blotting was performed as described previously. 12 Primary antibodies used were FSTL1 (sc-12542, Santa Cruz Biotechnology), DIP2A (sc-67556, Santa Cruz Biotechnology), phosphorylated Akt (Cell Signaling Technology), cleaved caspase-3 (Cell Signaling Technology), and goat polyclonal β-actin (sc-1616, Santa Cruz Biotechnology).
Statistical Analysis
Data from different groups were compared using 1-way ANOVA followed by post hoc Tukey tests. The data are presented as means±SEM. A value of P<0.05 was considered statistically significant.
Results
Expressions of FSTL1 and DIP2A Were Increased in Neurons and Peaked 24 Hours After MCAO
The protein level of FSTL1 and DIP2A at 6, 12, 24, and 48 hours in the ischemic penumbra after MCAO were measured by Western blot. Analysis showed that FSTL1 began increasing as early as 6 hours after ischemia, peaking at 12 hours, and was sustained to 24 hours (both 12 and 24 hours were statistically significant from sham, P<0.05). FSTL1 returned to a level indistinguishable from sham by 48 hours ( Figure 1A and 1B). A similar trend was observed for the expression of DIP2A, the FSTL1 receptor; DIP2A significantly increased at 12 and 24 hours after MCAO and returned backed to sham levels at 48 hours ( Figure 1C ). Double immunofluorescence staining of FSTL1 and NeuN or DIP2A and NeuN showed that both FSTL1 and DIP2A were upregulated in neurons in the penumbra 24 hours after MCAO. FSTL1 was primarily expressed in the cytoplasm, and DIP2A is located in the membranes of neurons ( Figure 1D ).
Recombinant FSTL1 Reduced Brain Infarction and Improved Neurological Function 24 and 72 Hours After MCAO
Analysis of the infarct stained with 2,3,5-triphenyltetrazolium chloride showed that the ratio of the infarcted tissue volume to the volume of the contralateral tissue 24 hours after MCAO was 0.334±0.1102. Administering the vehicle did not significantly reduce the infarct ratio (0.324±0.1302; P>0.05 versus MCAO). Treatment with the low dose of FSTL1 (100 mg/kg) had an infarct ratio of 0.2194±0.0395 (P>0.05 versus MCAO). However, treatment with the high dose of FSTL1 (300 mg/kg) significantly decreased the infarct ratio (Figure 2A and 2B ; 0.190±0.0397; P<0.05 versus MCAO).
MCAO resulted in neurological deficits 24 hours after MCAO (P<0.05 versus sham). Administering the vehicle or low dose of FSTL1 did not have any significant effect on neurological deficits. Yet, the high dose of FSTL1 significantly improved the neurological function of rats 24 hours after MCAO ( Figure 2C ; P<0.05 versus MCAO).
Seventy-two hours after MCAO, the infarct ratio was 0.3193±0.0775 in untreated group (MCAO) and 0.3222±0.0536 in the vehicle-treated group (MCAO+vehicle). FSTL1 at a dose of 300 mg/kg significantly decreased the infarct ratio compared with MCAO (0.151±0.0382; P<0.05 versus MCAO; Figure 3A and 3B). Furthermore, FSTL1 significantly improved the performance of MCAO rats on the neurobehavioral tests ( Figure 3C ; P<0.05 versus MCAO).
FSTL1 Decreased Neuronal Apoptosis Through Phosphorylation of Akt
Twenty-four hours after MCAO, there were abundant TUNEL-positive neurons in the ischemic penumbra, and 
FSTL1 Phosphorylation of Akt Is Dependent on Its Receptor DIP2A
DIP2A-siRNA was injected intracerebroventricularly 48 hours before MCAO, and rats were treated with FSTL1 1 hour after MCAO. DIP2A-siRNA abolished the effects of FSTL1 by increasing neuron apoptosis ( Figure 5A and 5B, increased TUNEL-positive neurons, P<0.05 versus MCAO+FSTL1+scramble-siRNA group) and increasing the neurological deficits ( Figure 5C ; P<0.05 versus MCAO+FSTL1+scramble-siRNA group). Western blot 
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analysis showed that DIP2A-siRNA reduced the expression of DIP2A, decreased the level of phosphorylation of Akt, and raised the level of cleaved caspase-3 ( Figure 6 ; P<0.05 versus MCAO+FSTL1+scramble-siRNA group).
Discussion
Apoptosis has been suggested to play a role in neuronal death after stroke in patients as well as in animal models of stroke. Cerebral ischemia triggers 2 general pathways of apoptosis: the intrinsic pathway that originates from mitochondrial release of cytochrome c and associated stimulation of caspase-3 and the extrinsic pathway that originates from the activation of cell surface death receptors and subsequent stimulation of caspase-8. 3 Neurons in the ischemic penumbra or peri-infarct zone undergo apoptosis within hours after stroke onset. Targeting and preventing apoptosis in the penumbra would seem to be a logical therapeutic goal for limiting cerebral infarct volume after stroke. In the present study, we showed that administration of recombinant FSTL1 can reduce infarction volume and improve neurological function by suppressing neuron apoptosis after MCAO in rats. We also found that the antiapoptotic mechanism of FSTL1 treatment is via decreased caspase-3 cleavage through phosphorylation of Akt by activation of the FSTL1 receptor, DIP2A. These observations suggested that treatment with FSTL1 might be a potential therapeutic intervention for reducing infarction in patients with ischemic stroke.
FSTL1 was originally identified from a transforming growth factor-responsive gene in osteoblast cells that have a follistatin-like domain. Although developmental studies have suggested that FSTL1 regulates organ tissue formation in embryos, 13 its functions in fully developed tissue have only been partially elucidated. FSTL1 has been reported to suppress cancer 14 and modulate inflammation 15 in animals. Recently, accumulating evidence indicates FSTL1 is cardiac protective after ischemia stress. Upregulation of FSTL1 transcription was observed in the hearts of Akt1 transgene-induced hypertrophy mice, 16, 17 and FSTL1 levels are increased in patients with acute coronary syndrome or heart failure. 7, 18, 19 In experimental cardiac ischemia, systemic administration of FSTL1 was protective and suggested to be antiapoptotic. 6 Additionally, administration of FSTL1 accelerated revascularization in the hind-limb ischemia model, and in vitro studies demonstrated an antiapoptotic effect of FSTL1 on primary endothelial cells. 5 The results of these studies suggest that FSTL1 functions as an antiapoptotic protein after ischemia. However, little is known about its function in cerebrovascular disease. We found that FSTL1 was endogenously expressed in brain and was robustly increased 12 hours after MCAO. FSTL1 was observed in the cytoplasm of neurons. This study also provides additional evidence of the antiapoptotic function of FSTL1 after ischemia. Administration of recombinant FSTL1 decreased infarction volume and improved neurological function by reducing apoptosis, and knockdown of FSTL1
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exacerbates these outcomes. Furthermore, FSTL1 was found to decrease apoptosis both in neurons and non-neuronal cells, suggesting that FSTL1 may play a role in other cell types after cerebral ischemia. The serine/threonine protein kinase Akt (also known protein kinase B) is a key regulator of cell growth and survival and is essential for cellular adaptation to stress. Therefore, Akt plays a role in several critical pathways making it a compelling target for neuroprotection after brain ischemia. FSTL1 has been implicated in the protection of cardiovascular cells from stress via the activation of phosphatidylinositol 3-kinase and Akt signaling. 6 In endothelial cells, FSTL1 activation of phosphatidylinositol 3-kinase/Akt signaling led to the activation of endothelial nitric oxide synthase and subsequent nitric oxide production. 5 In this study, it was found that recombinant FSTL1 increases the phosphorylation of Akt 24 hours after MCAO, and knockdown of FSTL1 has the reverse effect.
Although FSTL1 is categorized as a follistatin-like protein, there is relatively little functional similarity with other follistatin family proteins which are binding partners of the transforming 20 To determine the mechanism of FSTL1 in Akt phosphorylation after focal cerebral ischemia, we first examined the localization of DIP2A and FSTL1. We found that both DIP2A and FSTL1 were primarily expressed by neurons and increased 24 hours after MCAO, indicating that locally produced FSTL1 may activate signaling pathways through the DIP2A receptor. Knockdown of DIP2A by siRNA removed the antiapoptosis effects of FSTL1 via decreased the Akt phosphorylation after MCAO in rats.
In conclusion, our findings indicate that FSTL1 may contribute to neuronal survival after brain ischemia. FSTL1 inhibited apoptosis through phosphorylation of Akt via activation of its receptor, DIP2A. This study provides new information on the function of FSTL1 following MCAO and makes FSTL1 a potential therapeutic candidate for patients with ischemic stroke.
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